Intratympanic dexamethasone for profound idiopathic sudden sensorineural hearing loss

• Published in: Otolaryngology-head and neck surgery 2005-06, Vol.132 (6), p.902-905
• Main Author: Battista, Robert A.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Dexamethasone - administration & dosage; Female; Glucocorticoids - therapeutic use; Hearing Loss, Sensorineural - drug therapy; Humans; Injections, Intralesional; Male; Methylprednisolone - therapeutic use; Middle Aged; Prospective Studies
• ISSN: 0194-5998; 1097-6817
• DOI: 10.1016/j.otohns.2005.01.024

To determine hearing recovery by using intratympanic dexamethasone for profound, idiopathic sudden sensorineural hearing loss (ISSNHL). A prospective, clinical study was performed of 25 consecutive patients seen with profound ISSNHL. Patients received 4 intratympanic treatments of dexamethasone over the course of 2 weeks. Complete hearing recovery was defined as the final pure-tone average (PTA) within 10 dB of baseline. Partial recovery was defined as a final PTA with ≥50% hearing. The hearing in the contralateral ear was used as baseline. The average time to treatment was 28 days. Two patients had significant hearing recovery, and 1 additional patient had partial recovery. The 2 patients with significant hearing recovery were treated within 9 days of onset of hearing loss. By using the treatment protocol and definition of hearing recovery of this study, intratympanic dexamethasone does not result in significant hearing improvement for patients with profound ISSNHL. There is a possible trend for improved hearing results if intratympanic treatment is performed within 11 days of onset of hearing loss.